Pharvaris N.V. (PHVS) Cash Flow Statement

NASDAQ: PHVSOperating cash, capex, free cash flow and buybacks.

Where PHVS’s cash came from and went, 2025

December 31, 2025 · euros
Cash from operations
−€137.1M
Capital expenditures
€164,619
Free cash flow
−€137.2M
Returned to shareholders
—
Change in cash
€11.0M
cash at year-end €291.7M
Shares issued: €171.7MShares issued€171.7MCash used in operations: €137.1MCash used in operations€137.1M · 80%Other financing: €10.9MOther financing€10.9M · 6%Currency & other: €12.6MCurrency & other€12.6M · 7%Added to cash: €11.0MAdded to cash€11.0M · 6%Capital expenditures: €164,619Capital expenditures€164,619 · 0%€171.7M
Cash from operations
−€137.1M
Shares issued
+€171.7M
Other financing
−€10.9M
Currency & other
−€12.8M
Change in cash
€11.0M

Drawn to scale: where the cash came from and how it was used. Hover for values.

PHVS operating cash flow, capex and free cash flow

Operating cash flowCapital expendituresFree cash flowFCF margin (right axis)

PHVS cash flow trends, 2018–2025

Pharvaris N.V. cash flow trends
MetricTrendThenLatestChange
Operating cash flow−€3.9M2018−€137.1M2025—
Capital expenditures€13,4762018€164,6192025+43.0%/yr
Free cash flow−€3.9M2018−€137.2M2025—
Stock-based compensation€100,7452018€19.1M2025+111.5%/yr

Change is the average annual growth (CAGR) or the difference between the first and latest year.

PHVS cash flow by activity

OperatingInvestingFinancingChange in cash

PHVS net income vs operating cash flow

Net incomeOperating cash flow

Operating cash flow above net income usually means earnings are backed by cash (depreciation and stock-based pay are non-cash expenses).

PHVS cash flow statement in euros

Pharvaris N.V. annual cash flow statement
20252024202320222021202020192018
Operating activities
Net income−€173.7M−€132.4M−€99.8M−€75.7M−€42.7M−€26.1M−€8.0M−€4.3M
Depreciation & amortization€418,353€269,562€257,551€152,941€77,370€7,401€549€4.3M
Stock-based compensation€19.1M€16.2M€10.7M€11.3M€8.2M€1.6M€116,147€100,745
Change in working capital€7.6M€5.9M−€5.9M€8.4M€1.6M€1.6M€1.2M€291,547
Other non-cash items€9.5M−€10.1M€1.7M−€11.4M−€11.8M€1.4M−€3,693−€4.3M
Cash from operating activities−€137.1M−€120.1M−€93.0M−€67.2M−€44.6M−€21.5M−€6.7M−€3.9M
Investing activities
Capital expenditures−€164,619−€538,086−€89,984−€124,296−€130,032−€42,977−€13,476−€13,476
Investments (net)—−€538,086−€85,243−€124,296−€130,032−€42,977−€13,476€0
Acquisitions & other investing€0€538,086€85,243€124,296€130,032€42,977€13,476€0
Cash from investing activities−€164,619−€538,086−€89,984−€124,296−€130,032−€42,977−€13,476−€13,476
Financing activities
Net borrowing (repayment)−€219,013−€159,657−€220,507−€119,527−€119,527−€119,527−€119,527—
Shares issued€171.7M€2.2M€64.2M€9.6M€156.8M€102.5M€22.5M€4.5M
Other financing−€10.9M€592,000€261.4M−€839,970−€13.0M−€1.2M−€716,654€0
Cash from financing activities€160.6M€2.7M€325.4M€8.7M€143.7M€101.2M€21.6M€4.5M
Summary
Net change in cash€11.0M−€110.5M€229.4M−€47.5M€110.7M€78.3M€14.9M€590,198
Cash at end of period€291.7M€280.7M€391.2M€161.8M€209.4M€98.6M€20.3M€5.4M
Free cash flow−€137.2M−€120.7M−€93.1M−€67.3M−€44.7M−€21.5M−€6.7M−€3.9M

Negative numbers are cash paid out. Quarterly columns are labeled by the month the quarter ended. Figures in euros as reported; data from EODHD.

PHVS cash generation

In fiscal 2025 (ended December 31, 2025), Pharvaris generated -€137.1 million of cash from operations and spent €0.2 million on capital expenditures, leaving free cash flow of -€137.2 million. Cash and equivalents rose by €11.0 million over the year.

Related: PHVS income statement, PHVS balance sheet. See the PHVS stock overview for the latest quote and news.

PHVS cash flow FAQ

What is Pharvaris's free cash flow?

Pharvaris's free cash flow was -€137.2 million in fiscal 2025: -€137.1 million of operating cash flow minus €0.2 million of capital expenditures It was -€120.7 million a year earlier..

How much cash does Pharvaris generate from operations?

Pharvaris generated -€137.1 million of cash from operating activities in fiscal 2025.

How much does Pharvaris spend on capital expenditures?

Pharvaris spent €0.2 million on capital expenditures in fiscal 2025, compared with €0.5 million the year before.

Biotechnology: cash flow